Neuberger Berman Group LLC boosted its position in shares of Cantel Medical Corp. (NYSE:CMN) by 11.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,061,984 shares of the company’s stock after buying an additional 109,230 shares during the period. Neuberger Berman Group LLC owned approximately 2.57% of Cantel Medical Corp. worth $82,814,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Integrated Investment Consultants LLC raised its stake in shares of Cantel Medical Corp. by 2.1% in the third quarter. Integrated Investment Consultants LLC now owns 2,033 shares of the company’s stock worth $153,000 after buying an additional 41 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Cantel Medical Corp. by 0.6% in the third quarter. Louisiana State Employees Retirement System now owns 16,000 shares of the company’s stock worth $1,248,000 after buying an additional 100 shares during the period. Arizona State Retirement System raised its stake in shares of Cantel Medical Corp. by 0.5% in the third quarter. Arizona State Retirement System now owns 18,747 shares of the company’s stock worth $1,462,000 after buying an additional 100 shares during the period. LS Investment Advisors LLC raised its stake in shares of Cantel Medical Corp. by 7.5% in the second quarter. LS Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $104,000 after buying an additional 106 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Cantel Medical Corp. by 3.2% in the second quarter. ProShare Advisors LLC now owns 5,186 shares of the company’s stock worth $356,000 after buying an additional 160 shares during the period. 82.99% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Cantel Medical Corp. (NYSE:CMN)

Shares of Cantel Medical Corp. (NYSE:CMN) opened at 81.01 on Tuesday. Cantel Medical Corp. has a 1-year low of $55.01 and a 1-year high of $82.80. The company’s 50-day moving average is $75.11 and its 200 day moving average is $72.52. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of 56.34 and a beta of 1.41.

Cantel Medical Corp. (NYSE:CMN) last posted its earnings results on Thursday, September 29th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.11. Cantel Medical Corp. had a net margin of 9.02% and a return on equity of 16.70%. The business had revenue of $179 million for the quarter. During the same quarter in the previous year, the business posted $0.39 earnings per share. The business’s quarterly revenue was up 18.3% compared to the same quarter last year. On average, equities research analysts expect that Cantel Medical Corp. will post $1.96 EPS for the current fiscal year.

The company also recently announced a semiannual dividend, which will be paid on Tuesday, January 31st. Investors of record on Tuesday, January 17th will be paid a $0.07 dividend. The ex-dividend date is Thursday, January 12th. This is a positive change from Cantel Medical Corp.’s previous semiannual dividend of $0.06. This represents a yield of 0.18%. Cantel Medical Corp.’s dividend payout ratio (DPR) is presently 8.33%.

TRADEMARK VIOLATION WARNING: “Neuberger Berman Group LLC Has $82,814,000 Position in Cantel Medical Corp. (CMN)” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/29/neuberger-berman-group-llc-has-82814000-position-in-cantel-medical-corp-cmn.html.

Several research firms recently weighed in on CMN. Benchmark Co. set a $83.00 price objective on shares of Cantel Medical Corp. and gave the stock a “buy” rating in a research note on Saturday, October 1st. Needham & Company LLC began coverage on shares of Cantel Medical Corp. in a research note on Wednesday, August 24th. They set a “hold” rating on the stock.

In related news, Chairman Charles M. Diker sold 14,897 shares of the firm’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $78.76, for a total value of $1,173,287.72. Following the transaction, the chairman now directly owns 3,190,111 shares in the company, valued at approximately $251,253,142.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Charles M. Diker sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 20th. The shares were sold at an average price of $75.61, for a total transaction of $226,830.00. Following the completion of the transaction, the chairman now owns 3,171,270 shares in the company, valued at $239,779,724.70. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by corporate insiders.

About Cantel Medical Corp.

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

5 Day Chart for NYSE:CMN

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.